KR101941645B1 - Lactic acid bacteria strains derived from human body with excellent resistance to environmental stress and Method for producing yogurt using it - Google Patents
Lactic acid bacteria strains derived from human body with excellent resistance to environmental stress and Method for producing yogurt using it Download PDFInfo
- Publication number
- KR101941645B1 KR101941645B1 KR1020160109879A KR20160109879A KR101941645B1 KR 101941645 B1 KR101941645 B1 KR 101941645B1 KR 1020160109879 A KR1020160109879 A KR 1020160109879A KR 20160109879 A KR20160109879 A KR 20160109879A KR 101941645 B1 KR101941645 B1 KR 101941645B1
- Authority
- KR
- South Korea
- Prior art keywords
- lactic acid
- mixture
- fermented milk
- acid bacteria
- weight
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 128
- 241000894006 Bacteria Species 0.000 title claims abstract description 74
- 239000004310 lactic acid Substances 0.000 title claims abstract description 64
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 64
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 26
- 230000006353 environmental stress Effects 0.000 title abstract description 18
- 235000013618 yogurt Nutrition 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 72
- 235000015140 cultured milk Nutrition 0.000 claims abstract description 58
- 241000186660 Lactobacillus Species 0.000 claims abstract description 34
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 33
- 241000194033 Enterococcus Species 0.000 claims abstract description 24
- 238000001816 cooling Methods 0.000 claims abstract description 18
- 239000010779 crude oil Substances 0.000 claims abstract description 18
- 239000007858 starting material Substances 0.000 claims abstract description 18
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 230000001954 sterilising effect Effects 0.000 claims abstract description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 26
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 25
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 25
- 239000006041 probiotic Substances 0.000 claims description 11
- 235000018291 probiotics Nutrition 0.000 claims description 11
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 9
- 230000000529 probiotic effect Effects 0.000 claims description 9
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims description 7
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 4
- 235000020129 lassi Nutrition 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 abstract description 17
- 230000002401 inhibitory effect Effects 0.000 abstract description 15
- 230000000968 intestinal effect Effects 0.000 abstract description 14
- 230000005855 radiation Effects 0.000 abstract description 12
- 102000004190 Enzymes Human genes 0.000 abstract description 11
- 108090000790 Enzymes Proteins 0.000 abstract description 11
- 210000004051 gastric juice Anatomy 0.000 abstract description 10
- 210000000941 bile Anatomy 0.000 abstract description 9
- 230000036542 oxidative stress Effects 0.000 abstract description 9
- 210000003608 fece Anatomy 0.000 abstract description 8
- 239000012530 fluid Substances 0.000 abstract description 4
- 238000005057 refrigeration Methods 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 description 24
- 239000011651 chromium Substances 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 102000006995 beta-Glucosidase Human genes 0.000 description 6
- 108010047754 beta-Glucosidase Proteins 0.000 description 6
- 229910052793 cadmium Inorganic materials 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 102000053187 Glucuronidase Human genes 0.000 description 5
- 108010060309 Glucuronidase Proteins 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 5
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 5
- 229910052804 chromium Inorganic materials 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000001179 sorption measurement Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 229960001334 corticosteroids Drugs 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 241000194031 Enterococcus faecium Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 231100000987 absorbed dose Toxicity 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000003113 dilution method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 229910052745 lead Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000002438 stress hormone Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000002820 sympathetic nervous system Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000593806 Phyllis Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- QZPSXPBJTPJTSZ-UHFFFAOYSA-N aqua regia Chemical compound Cl.O[N+]([O-])=O QZPSXPBJTPJTSZ-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A23Y2220/73—
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 환경스트레스 저항성이 우수한 인체유래유산균을 이용한 발효유의 제조방법에 관한 것으로, 성인분변으로부터 분리되고, 산화적 스트레스, 중금속 및 방사선 저항성이 우수하며, 장내유해효소 억제 활성을 가지고, 프로바이오틱스 유산균이 되기 위하여 인공위액 및 인공담즙액 저항성이 우수한 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54 및 락토바실러스 애시도필러스 L120 균주를 제공한다.
환경스트레스 저항성이 우수한 인체유래유산균을 이용한 발효유의 제조방법은 원유, 설탕, 상기 균주를 준비하는 준비단계와; 상기 준비단계에서 준비한 원유 100중량부에 대하여 설탕 4~6중량부를 혼합하여 혼합물을 제조하는 혼합단계와; 상기 혼합물을 85~95℃의 온도로 5~15분간 살균하는 살균단계와; 상기 살균된 혼합물을 40~45℃로 냉각시키는 냉각단계와; 상기 냉각된 혼합물 100중량부에 대하여 스타터로 유산균 1중량부를 접종하는 접종단계와; 상기 스타터가 접종된 혼합물을 최종 pH가 4.3~4.6이 될 때까지 35~45℃의 온도로 6~8시간 동안 발효시켜 발효유를 만드는 발효단계와; 상기 발효된 발효유를 15~20℃로 냉각시키는 발효유 냉각단계와; 상기 냉각된 발효유를 3~5℃의 온도로 냉장저장하는 냉장단계: 를 포함하여 구성한다. The present invention relates to a method for producing fermented milk using human lactic acid bacteria having excellent environmental stress resistance, which is isolated from adult feces, has excellent oxidative stress, heavy metals and radiation resistance, has an intestinal harmful enzyme inhibitory activity, Lactobacillus laminosus L3, Enterococcus lassus L54, and Lactobacillus aspirophilus L120 strains, which are excellent in artificial gastric juice and artificial bile fluid resistance, are provided.
A method for producing fermented milk using human-derived lactic acid bacteria having excellent environmental stress resistance comprises the steps of preparing crude oil, sugar, and the strain; Mixing 4 to 6 parts by weight of sugar with respect to 100 parts by weight of crude oil prepared in the preparing step to prepare a mixture; Sterilizing the mixture at a temperature of 85 to 95 DEG C for 5 to 15 minutes; Cooling the sterilized mixture to 40-45 < 0 >C; 100 parts by weight of the cooled mixture is inoculated with 1 part by weight of lactic acid bacteria as a starter; Fermenting the fermented milk by fermenting the mixture to which the starter has been inoculated at a temperature of 35 to 45 DEG C for 6 to 8 hours until the final pH is 4.3 to 4.6; A fermented milk cooling step of cooling the fermented milk to 15 to 20 캜; And a refrigeration step of refrigerating and storing the cooled fermented milk at a temperature of 3 to 5 ° C.
Description
본 발명은 환경 스트레스에 저항성이 우수한 인체유래유산균 및 이를 이용한 발효유의 제조방법에 관한 것으로써, 성인분변으로부터 분리되고, 산화적 스트레스, 중금속 및 방사선 저항성이 우수하며, 장내유해효소 억제 활성을 가지고, 프로바이오틱스 유산균이 되기 위하여 인공위액 및 인공담즙액 저항성이 우수한 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54 및 락토바실러스 애시도필러스 L120 균주등을 함유하는 기능성 발효유의 제조방법에 관한 것이다. The present invention relates to a human lactic acid bacterium having excellent resistance to environmental stress, and a method for producing fermented milk using the same, which is isolated from adult feces, has excellent oxidative stress, heavy metals and radiation resistance, Lactobacillus lansos L3, Enterococcus lassus L54 and Lactobacillus acidophilus strain L120, which are excellent in artificial gastric juice and artificial bile fluid resistance to be probiotic lactic acid bacteria, and the like.
치열한 경쟁사회를 살아가는 대부분의 현대인들은 지나친 스트레스에 항상 노출되어 있다. 인체를 비롯한 자연계의 모든 생명체는 다양한 환경 스트레스 조건에 노출되었을 때 빠르게 활성산소종(Reactive oxygen species, ROS)을 생성하면서 항산화 방어기전의 균형을 깨트리고, 산화적 스트레스를 유발하여 세포 및 조직손상을 비롯한 만성퇴행성 질환을 일으키게 된다. Most modern people living in a fiercely competitive society are always exposed to excessive stress. All living organisms, including humans, are able to rapidly produce reactive oxygen species (ROS) when exposed to a variety of environmental stress conditions, breaking the balance of antioxidant defenses and inducing oxidative stress, Resulting in chronic degenerative diseases.
또한 식품을 통해 섭취되는 크롬(Cr), 납(Pb), 카드뮴(Cd) 등의 유해중금속은 인체 내에 들어가면 쉽게 배출되지가 않고 낮은 농도로도 인체조직과 반응하여 독성을 나타내기 때문에 현대 식품 사회에 큰 문제가 되고 있다. In addition, harmful heavy metals such as Cr (Cr), lead (Pb), and cadmium (Cd) ingested through foods are not easily released into the human body and react with human tissues even at low concentrations, Has become a big problem.
최근 방사선 및 방사성 동위원소가 의학, 농업, 공업 등 다양한 분야에서 널리 사용되고 있음에 따라 이 분야에 관련된 사람들의 방사선 피폭 기회가 증가하였으며, 방사선을 이용한 항암치료도 증가하는 추세에 있다. 특히 방사선에 인체가 노출되면 이로 인한 직접적인 DNA 손상이 일어나거나, 활성산소에 의한 간접적 세포손상이 유도된다. Recently, as radiation and radioactive isotopes are widely used in various fields such as medicine, agriculture, and industry, opportunities for radiation exposure of people involved in this field are increased and chemotherapy using radiation is also increasing. In particular, direct exposure of the body to radiation causes DNA damage or induces indirect cell damage by reactive oxygen species.
한편 스트레스를 받으면 교감신경이 활성화되면서 스트레스호르몬인 부신피질호르몬(corticosteroid)이 많이 분비되는데 이러한 부신피질호르몬은 소화관 운동과 소화액 분비를 방해해 장내유해균의 증식을 유도하여 장내유해균이 생산하는 베타글루코시데이즈(β-Glucosidase), 베타글루쿠로니데이즈(β-Glucuronidase) 및 트립토파네이즈(Tryptophanase) 효소 활성이 증가하게 된다. On the other hand, under stress, the sympathetic nervous system is activated and a lot of corticosteroids, which are stress hormones, are secreted. These corticosteroids interfere with digestive tract exercise and digestive juice secretion and induce the proliferation of intestinal harmful bacteria. Beta-glucosidase, beta-glucuronidase, and tryptophanase enzymes.
대표적인 장수식품인 발효유는 우유의 영양성분 이외에 프로바이오틱스 유산균의 작용에 의해 생성된 유기산, 아미노산, 펩티드, 미량의 생리활성물질과 유산균체가 포함되어 있어 식품으로서의 영양뿐만 아니라, 장내 유해 세균의 억제와 장의 기능성 향상, 장내균총의 균형유지와 정장작용, 면역계의 자극에 의한 항암 효과, 혈중 콜레스테롤의 저하 효과 등 현대인의 성인병 예방과 건강 증진에 탁월한 기능을 나타내는 것으로 보고되고 있다. Fermented milk, which is a typical long-lived food, contains not only nutritional components of milk, but also organic acids, amino acids, peptides, trace amounts of physiologically active substances and lactic acid bacteria produced by the action of probiotic lactic acid bacteria, It has been reported that it exhibits excellent functions for the prevention of adult diseases and promotion of health in modern people such as improvement of intestinal microflora, stabilization of intestinal microflora, effect of anti-cancer by stimulation of immune system, and lowering of blood cholesterol.
한편, 한국인의 장내에 서식하는 유산균을 분리하여 다양한 환경스트레스에 저항성을 확인하고 발효유 제조를 위한 한국형 스타터 및 이를 이용한 발효유 제조방법이 없었다.On the other hand, there is no Korean starter for fermented milk production and fermented milk production method using the same to confirm the resistance to various environmental stresses by isolating the lactic acid bacteria living in the intestines of Korean people.
본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위한 것으로서, 항스트레스 효과가 우수한 발효유 제품을 개발하기 위하여 한국인의 장내에 서식하는 유산균을 분리하여 다양한 환경스트레스 저항성을 확인하고 발효유 제조를 위한 한국형 스타터를 개발하고자 한다. In order to develop a fermented milk product having excellent anti-stress effect, the present invention is to solve the environmental stress resistance by separating the lactic acid bacteria living in the intestines of Korean, .
또한 본 발명은 활성산소종에 의한 산화적 스트레스 저항성이 우수하고, 인체에 흡수되어 축적되려는 유해중금속 물질들을 효과적으로 제거할 수 있으며, 방사선 피폭에 의한 손상으로부터 효과적으로 세포를 보호할 수 있을 뿐만 아니라 스트레스로 인한 장내유해균의 증식을 억제함으로써 효과적으로 장내환경을 개선할 수 있는 환경스트레스 저항성이 우수한 인체유래유산균을 이용한 발효유의 제조방법을 제공한다. In addition, the present invention provides a method for effectively removing harmful heavy metal materials which are excellent in oxidative stress resistance due to active oxygen species and absorbed and accumulated in a human body, effectively protecting cells from damage caused by radiation exposure, The present invention also provides a method for producing fermented milk using the human-derived lactic acid bacterium which is capable of effectively improving the intestinal environment by inhibiting the growth of harmful bacteria in the intestines caused by the bacteria.
상기와 같은 목적을 달성하기 위하여 본 발명은 성인분변으로부터 분리되고, 산화적 스트레스, 중금속 및 방사선 저항성이 우수하며, 장내유해효소 억제 활성을 가지고, 프로바이오틱스 유산균이 되기 위하여 인공위액 및 인공담즙액 저항성이 우수한 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54 및 락토바실러스 애시도필러스 L120 균주를 제공한다. In order to achieve the above object, the present invention provides a method for producing a probiotic lactic acid bacterium, which is isolated from adult feces, has excellent oxidative stress, heavy metals and radiation resistance, has an inhibitory activity against intestinal harmful enzymes, Superior Lactobacillus laminocus L3, Enterococcus pathum L54, and Lactobacillus acidophilus L120 strains.
또한 본 발명은 원유, 설탕, 상기 균주를 준비하는 준비단계와; 상기 준비단계에서 준비한 원유 100중량부에 대하여 설탕 4~6중량부를 혼합하여 혼합물을 제조하는 혼합단계와; 상기 혼합물을 85~95℃의 온도로 5~15분간 살균하는 살균단계와; 상기 살균된 혼합물을 40~45℃로 냉각시키는 냉각단계와; 상기 냉각된 혼합물 100중량부에 대하여 스타터로 유산균 1중량부를 접종하는 접종단계와; 상기 스타터가 접종된 혼합물을 최종 pH가 4.3~4.6이 될 때까지 35~45℃의 온도로 6~8시간 동안 발효시켜 발효유를 만드는 발효단계와; 상기 발효된 발효유를 15~20℃로 냉각시키는 발효유 냉각단계와; 상기 냉각된 발효유를 3~5℃의 온도로 냉장저장하는 냉장단계: 를 포함하여 구성되는 것을 특징으로 한다. The present invention also relates to a method for preparing crude oil, sugar and the strain, Mixing 4 to 6 parts by weight of sugar with respect to 100 parts by weight of crude oil prepared in the preparing step to prepare a mixture; Sterilizing the mixture at a temperature of 85 to 95 DEG C for 5 to 15 minutes; Cooling the sterilized mixture to 40-45 < 0 >C; 100 parts by weight of the cooled mixture is inoculated with 1 part by weight of lactic acid bacteria as a starter; Fermenting the fermented milk by fermenting the mixture to which the starter has been inoculated at a temperature of 35 to 45 DEG C for 6 to 8 hours until the final pH is 4.3 to 4.6; A fermented milk cooling step of cooling the fermented milk to 15 to 20 캜; And cooling the cooled fermented milk at a temperature of 3 to 5 占 폚.
본 발명에 의한 환경스트레스 저항성이 우수한 인체유래유산균을 이용한 발효유 제조방법은 활성산소종에 의한 산화적 스트레스 저항성이 우수하고, 인체에 흡수되어 축적되려는 유해중금속 물질들을 효과적으로 제거할 수 있으며, 방사선 피폭에 의한 손상으로부터 효과적으로 세포를 보호할 수 있을 뿐만 아니라 스트레스로 인한 장내유해균의 증식을 억제함으로써 효과적으로 장내환경을 개선할 수 있는 기능성 발효유를 제공할 수 있다는 효과가 있다. The fermented milk production method using lactic acid bacteria derived from human body having excellent environmental stress resistance according to the present invention is excellent in oxidative stress resistance due to active oxygen species and can effectively remove harmful heavy metal substances to be absorbed and accumulated in human body, It is possible to provide a functional fermented milk which is capable of effectively protecting cells from damage due to stress and inhibiting the growth of harmful bacteria in the intestines due to stress, thereby effectively improving intestinal environment.
도 1은 본 발명의 실시 예에 의한 선별균주에 방사선을 조사한 후 생균수 측정을 통해 생존율을 비교한 그래프.
도 2 (2a~2c)는 본 발명의 실시예에 의한 선별균주에 베타글루코시데이즈(β-Glucosidase), 베타글루쿠로니데이즈(β-Glucuronidase), 트립토파네이즈(Tryptophanase) 효소의 억제 활성을 측정한 그래프.
도 3 (3a-3b)은 본 발명의 실시예에 의한 선별균주에 인공위액 및 인공담즙 저항성을 측정한 그래프.
도 4는 본 발명의 실시예에 의한 환경스트레스에 대한 저항성이 우수한 인체유래유산균을 이용하여 제조한 발효유의 제조방법을 도시한 순서도.BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph comparing survival rates of viable cell counts after irradiating a screening strain according to an embodiment of the present invention with radiation. FIG.
2 (2a-2c) show the inhibitory activity of beta-glucosidase, beta-glucuronidase, and tryptophanase enzymes on the screening strain according to the embodiment of the present invention Measured graph.
FIG. 3 (3a-3b) is a graph showing artificial gastric juice resistance and artificial bile resistance in a screening strain according to an embodiment of the present invention.
FIG. 4 is a flowchart showing a method for producing fermented milk produced by using a human-derived lactic acid bacterium having excellent resistance to environmental stress according to an embodiment of the present invention. FIG.
이하, 본 발명의 환경스트레스에 저항성이 우수한 인체유래유산균 및 이를 이용한 발효유 제조방법에 관하여 상세히 설명하면 다음과 같다.
- 미생물 기탁일 및 기탁 번호 : 2016년 08월 3일 / KCTC18485P for L3
- 미생물 기탁일 및 기탁 번호 : 2016년 08월 3일 / KCTC18486P for L54
- 미생물 기탁일 및 기탁 번호 : 2016년 08월 3일 / KCTC18487P for L120Hereinafter, a human-derived lactic acid bacterium having excellent resistance to environmental stress and a method for producing fermented milk using the same will be described in detail as follows.
- Date of deposit of microorganism and deposit number: August 3, 2016 / KCTC18485P for L3
- Date of donation of microorganism and deposit number: August 3, 2016 / KCTC18486P for L54
- Date of deposit of microorganism and deposit number: August 3, 2016 / KCTC18487P for L120
본 발명을 설명함에 있어서, 원유라 함은, 발효유 제조를 위해 홀스타인 프리지안(Holstein-Friesian)종에서 생산된 산도가 0.14 ~ 0.15%이고, pH가 6.6 ~ 6.8 범위인 신선한 원유를 말한다.In describing the present invention, the term crude refers to fresh crude oil having an acidity of 0.14 to 0.15% and a pH in the range of 6.6 to 6.8 produced from Holstein-Friesian species for the production of fermented milk.
<동작설명 1> 환경스트레스 저항성이 우수한 균주 선발<Description of operation 1> Selection of a strain having excellent environmental stress resistance
1-1. 한국인 성인분변에서 유산균 분리1-1. Separation of lactic acid bacteria from feces of Korean adults
장수노인의 장내에 서식하는 다양한 스트레스에 저항성이 우수한 균주를 분리하기 위하여 미리 정한 지역, 예를 들어 순창지역 장수노인 21명으로부터 분변을 채취하여, 멸균 PBS 완충용액(10 mM, pH 7.3)에 현탁한 후 멸균생리식염수로 희석하였다. 희석액은 MRS 고체배지에 도말한 다음 37℃에서 72시간동안 혐기배양하였다. MRS 고체배지 상에 나타난 특징적인 콜로니를 1차적으로 순수 분리하여 233개 균주를 획득하였으며, 분리한 균주들은 15% glycerol에 현탁하고 70℃에 보관하며 실험에 사용하였다.In order to isolate strains resistant to various stresses in the intestinal longevity of elderly people, feces were collected from a predetermined area, for example, 21 elderly people in Sunchang area, and suspended in sterile PBS buffer (10 mM, pH 7.3) And then diluted with sterile physiological saline. The diluted solution was plated on MRS solid medium and anaerobically incubated at 37 ° C for 72 hours. 233 strains were obtained by purely isolating the characteristic colonies on the MRS solid medium. The isolated strains were suspended in 15% glycerol and stored at 70 ℃.
1-2. 산화적 스트레스 저항성이 우수한 유산균 선발1-2. Selection of lactic acid bacteria with excellent oxidative stress resistance
성인분변에서 분리한 233개의 균주를 대상으로 1차적으로 활성산소종(reactive oxygen species, ROS)에 의한 산화적 스트레스에 저항성이 우수한 유산균을 선발하기 위하여 대표적인 활성산소인 과산화수소(hydrogen peroxide; H2O2)를 처리하였다. In order to select lactic acid bacteria resistant to oxidative stress caused by reactive oxygen species (ROS), 233 strains isolated from adult feces were treated with hydrogen peroxide (H 2 O 2 ) was treated.
구체적으로 분리균주를 MRS 액체배지에 2% 접종하고 37℃에서 24시간 동안 정치배양한 후 phosphate buffered saline (PBS)으로 2회 세척하여 세포수 약 107 CFU/ml 수준이 되도록 동일한 buffer에 현탁시켰다. 1mM hydrogen peroxide 500ul와 동량의 세포현탁액을 즉시 혼합하여 37℃에서 2시간 반응시킨 후 단계별로 희석하고 BCP 고체배지에 도말한 후 37℃에서 24시간 동안 혐기배양하여 생성된 콜로니 수를 측정하였다. 이때 생존율(%)은 [(실험구의 Log 지수값/대조구의 Log 지수값)×100]로 나타내었으며, 대조구는 과산화수소 무처리구로 설정하였다.Specifically, the isolate was inoculated 2% in MRS liquid medium, incubated at 37 ° C for 24 hours, washed twice with phosphate buffered saline (PBS), and suspended in the same buffer to a cell number of about 10 7 CFU / ml . The cells were incubated at 37 ° C for 2 hours. Cells were incubated at 37 ° C for 24 hours, and the number of colonies formed was measured. The survival rate (%) was expressed as [(Log index value of experimental group / log index value of control group) × 100], and the control group was set as a hydrogen peroxide treatment group.
하기 표 1에 나타낸 바와 같이, 233개 균주 중 20개 균주는 현재 생균활성제 또는 발효유에 널리 사용되고 있는 락토바실러스 람노서스 GG(LGG) 균주와 유사하게 1mM 농도의 과산화수소 처리 조건에서도 100%의 높은 생존율을 나타내었다. As shown in Table 1 below, 20 strains out of 233 strains have a high survival rate of 100% even under the condition of 1 mM of hydrogen peroxide, similar to Lactobacillus lambusus GG (LGG) strains widely used in live bacteria or fermented milk Respectively.
따라서 활성산소에 높은 내성을 나타내는 20개 균주를 대상으로 2차 선발실험을 진행하였다.Therefore, the second selection experiment was carried out on 20 strains which showed high tolerance to reactive oxygen species.
명Strain
persons
율
(%)survival
rate
(%)
명Strain
persons
율
(%)survival
rate
(%)
명Strain
persons
율
(%)survival
rate
(%)
명Strain
persons
율
(%)survival
rate
(%)
명Strain
persons
율
(%)survival
rate
(%)
명Strain
persons
율
(%)survival
rate
(%)
1-3. 중금속 저항성이 우수한 유산균 선발1-3. Selection of lactic acid bacteria with excellent resistance to heavy metals
식품을 통해 섭취되는 크롬(Cr), 납(Pb), 카드뮴(Cd) 등의 유해중금속은 인체 내에 들어가면 쉽게 배출되지가 않고 낮은 농도로도 인체조직과 반응하여 독성을 나타내기 때문에 중금속 흡착능이 우수한 유산균을 이용하여 인체에 흡수되어 축적되려는 유해중금속 물질들을 효과적으로 제거하고자 하였다.Harmful heavy metals such as chromium (Cr), lead (Pb), and cadmium (Cd), which are ingested through foods, are not easily released into the human body and react with human tissues even at low concentrations, And to remove harmful heavy metal substances which are absorbed by the human body and accumulated by using lactic acid bacteria.
구체적으로 분리균주들의 중금속 저항성을 알아보기 위하여 크롬(Cr), 납(Pb), 카드뮴(Cd)을 최종농도 0.01%가 되도록 MRS 액체배지에 첨가한 다음 유산균을 접종하여 37℃에서 24시간 동안 정치배양한 후 660nm에서 흡광도를 측정하였다. 이때 생존율(%)은 [(실험구의 흡광도 값/대조구의 흡광도 값)×100]로 나타내었으며, 대조구는 중금속 무처리구로 설정하였다. Specifically, Cr, Pb, and Cd were added to the MRS liquid medium to a final concentration of 0.01%, and then lactic acid bacteria were inoculated and incubated at 37 ° C for 24 hours After incubation, absorbance was measured at 660 nm. The survival rate (%) was expressed as [(absorbance value of the experimental group / absorbance value of the control) × 100], and the control group was set as the heavy metal untreated group.
또한 균체에 흡착되어 존재하는 중금속의 농도를 확인하기 위하여 중금속 저항성을 조사한 유산균 배양액을 원심분리(3000rpm, 10 min)하여 상층액을 제거한 다음 균체(Pellet)를 회수하였다. 각 균체 시료에 왕수 14㎖(35% HCl 10.5㎖, 70% HNO3 3.5㎖)를 첨가하여 상온에서 16시간 이상 방치한 후 60℃에서 2시간 반응시키고, 상온에서 냉각하였다. 이후 1% 질산용액 10㎖에 녹여 희석한 시료를 ICP-OES(iCAP6200DUO, Thermo Fisher Scientific, UK)에 주입하여 정량 분석을 실시하였다.In order to confirm the concentration of heavy metals adsorbed on the cells, the culture solution of the lactic acid bacteria having heavy metal resistance was centrifuged (3000 rpm, 10 min) to remove the supernatant and the pellet was recovered. 14 ml of aqua regia (10.5 ml of 35% HCl, 3.5 ml of 70% HNO 3 ) was added to each bacterial cell sample, allowed to stand at room temperature for 16 hours or more, reacted at 60 ° C for 2 hours and cooled at room temperature. Then, the diluted samples were dissolved in 10 ml of 1% nitric acid solution and injected into ICP-OES (iCAP6200DUO, Thermo Fisher Scientific, UK) for quantitative analysis.
하기 표 2에 나타낸 바와 같이, 크롬(Cr) 처리구에서는 B40 균주와 L3 균주가 각각 99%, 94%의 높은 생육을 나타냈으며, 납(Pb) 처리구에서는 20개 균주 모두 전반적으로 높은 생육을 나타냈다. 또한 카드뮴(Cd) 처리구에서는 L72 균주, B40 균주 및 L3 균주가 각각 58%, 49%, 48%의 생육을 나타내었다. 특히 균체에 흡착된 중금속의 무게를 산출하여 흡착능을 확인한 결과 L3 균주가 크롬(Cr), 납(Pb), 카드뮴(Cd) 처리구에서 각각 916ug/ml, 153mg/ml, 767ug/ml의 높은 중금속 흡착능을 나타내었다. 따라서 L3 균주는 3가지 유해중금속을 효과적으로 흡착시켜 중금속들이 체내에 축적되는 것을 저해할 수 있을 것으로 판단된다.As shown in the following Table 2, B40 strain and L3 strain showed high growth rate of 99% and 94% in chromium (Cr) treatment and 20 strains in lead (Pb) treatment, respectively. In the cadmium (Cd) treatment, L72 strain, B40 strain and L3 strain showed growth of 58%, 49% and 48%, respectively. In particular, the weight of heavy metals adsorbed on the cells was measured and the adsorption capacity was confirmed. As a result, the L3 strain showed high heavy metal adsorption capacity of 916 ug / ml, 153 mg / ml and 767 ug / ml in the Cr, Pb and Cd treatments Respectively. Therefore, the L3 strain effectively adsorbs three harmful heavy metals, which may inhibit accumulation of heavy metals in the body.
(%)Survival rate
(%)
(ug/ml)Adsorption capacity
(ug / ml)
(%)Survival rate
(%)
(mg/ml)Adsorption capacity
(mg / ml)
(%)Survival rate
(%)
(ug/ml)Adsorption capacity
(ug / ml)
1-4. 방사선 저항성이 우수한 유산균 선발1-4. Selection of lactic acid bacteria with excellent radiation resistance
방사선에 인체가 노출되면 이로 인한 직접적인 DNA 손상이 일어나거나, 활성산소에 의한 간접적 세포손상을 일으키는 것으로 알려졌다. 따라서 방사선 항암치료시 방사선에 의한 장점막 손상으로부터 세포를 보호하고자 방사선에 대한 저항성이 우수한 유산균을 선발하였다. It is known that exposure to human radiation causes direct DNA damage resulting from this, or indirect cell damage caused by reactive oxygen species. Therefore, in order to protect the cells from damage to the intestinal mucosa by radiation, radiopharmaceuticals were selected for their resistance to radiation.
구체적으로 분리균주 배양액에 Co-60 감마선을 조사한 후 생균수 측정을 통해 생존율을 비교하였다. 감마선 조사는 한국원자력연구원 방사선과학연구소(Jeongeup, Korea)내 선원 11.1 PBq, Co-60 감마선 조사시설(point source AECL, IR-79, MDS Nordion InternationalCo., Ltd., Canada)을 이용하여 선량률 3 kGy의 흡수선량을 얻도록 하였다. 흡수선량의 확인은 alanine dosimeter (5 mm, Bruker Instruments,germant)를 사용하였으며, 흡수선량의 오차는 ±5% 이내였다. 감마선을 조사한 배양액 0.1mL에 멸균식염수 0.9ml을 첨가한 다음 십진 희석법으로 희석한 뒤 BCP 한천배지를 이용하여 평판배양법으로 37℃에서 48시간 동안 배양하였다. 그 후 생성된 콜로니 수를 측정하여 생존율(%) [(실험구의 Log 지수값/대조구의 Log 지수값)×100]로 나타내었다. 이때 대조구는 감마선 무처리구로 설정하였다. Specifically, survival rates of the isolates were measured by counting viable cells after irradiation with Co-60 gamma-ray. Gamma irradiation was performed using a source of 11.1 PBq and a Co-60 gamma ray irradiation facility (point source AECL, IR-79, MDS Nordion International Co., Ltd., Canada) at the Korea Atomic Energy Research Institute (Jeongeup, Korea) To obtain the absorbed dose. Absorbed doses were checked using an alanine dosimeter (5 mm, Bruker Instruments, Germany) and the error of the absorbed dose was within ± 5%. 0.9 ml of sterilized saline was added to 0.1 ml of the gamma-irradiated culture, followed by dilution with decidual dilution method, followed by incubation at 37 ° C for 48 hours using a BCP agar plate culture method. The number of generated colonies was then measured and expressed as the survival rate (%) [(log index value of experimental group / Log index value of control group) x 100]. At this time, the control was set as a non-treated gamma ray.
도 1에 나타낸 바와 같이, 분리균주 배양액에 감마선을 조사한 결과 락토바실러스 람노서스 GG(LGG) 균주를 포함한 대부분의 균주들은 40% 내외의 생존율을 나타낸 반면 L120 균주가 67%의 가장 높은 생존율을 나타냈으며, 다음으로 L54 균주가 51%의 생존율을 나타냈다. 따라서 L120 균주는 방사선 피폭에 의한 손상으로부터 효과적으로 세포를 보호할 수 있을 것으로 판단된다.As shown in FIG. 1, most strains including Lactobacillus rhamnosus GG (LGG) showed a survival rate of about 40%, while L120 strains showed the highest survival rate of 67% , Followed by L54 strain with 51% survival rate. Therefore, the L120 strain is considered to be able to effectively protect cells from damage caused by radiation exposure.
1-5. 장내유해효소 활성억제 효과가 우수한 유산균 선발1-5. Selection of lactic acid bacteria with excellent inhibitory activity against enteric enzyme activity in intestines
스트레스를 받으면 교감신경이 활성화되면서 스트레스호르몬인 부신피질호르몬 (corticosteroid)이 많이 분비되는데 이러한 부신피질호르몬은 소화관 운동과 소화액 분비를 방해해 장내유해균의 증식을 유도하게 된다. 따라서 장내유해효소 활성억제 효과가 우수한 유산균을 선발하여 스트레스로 인한 장내유해균의 증식을 억제함으로써 장내환경을 개선하고자 하였다. When stressed, the sympathetic nervous system is activated and a lot of corticosteroids, which are stress hormones, are secreted. These corticosteroids interfere with digestive tract exercise and digestive juice secretion, leading to the proliferation of endemic bacteria in the intestines. Therefore, we selected lactic acid bacteria with excellent inhibitory effect on intestinal toxic enzyme activity and tried to improve intestinal environment by suppressing the growth of intestinal harmful bacteria caused by stress.
구체적으로 장내유해효소 활성억제 효과를 비교하기 위하여 장내유해균이 생산하는 베타글루코시데이즈(β-Glucosidase), 베타글루쿠로니데이즈(β-Glucuronidase), 트립토파네이즈(Tryptophanase) 효소의 억제 활성을 측정하였다.Specifically, the inhibitory activity of β-glucosidase, β-Glucuronidase, and Tryptophanase enzymes produced by enteropathogenic bacteria in the intestine was measured to compare the inhibitory effect of intestinal toxic enzyme activity Respectively.
유산균배양액에 건강한 성인분변 10배 희석액을 0.1ml 첨가하여 37℃에서 24시간 배양한 후 원심분리(3,000rpm, 5min)하여 균체를 멸균된 생리식염수에 현탁한 것을 효소액으로 사용하였다.0.1 ml of a 10-fold dilution of healthy adult feces was added to the culture solution of lactic acid bacteria, followed by incubation at 37 ° C for 24 hours, followed by centrifugation (3,000 rpm, 5 min) to suspend the cells in sterilized physiological saline.
또한 베타글루코시데이즈(β-Glucosidase) 억제 활성 측정은 0.1M Sodium phosphate buffer(pH7.0) 0.3ml에 2mM pnitrophenyl-β-D-glucopyranoside 0.2ml과 효소액 0.1ml을 첨가하여 37℃ shaking water bath에서 30분간 반응시킨 후, 0.5N NaOH 0.3ml를 첨가하여 반응을 종료시켰다. 이후 원심분리(13,000rpm, 5min)한 상등액을 이용하여 405nm에서 흡광도를 측정하였다. The inhibitory activity of β-glucosidase was determined by adding 0.2 ml of 2 mM pnitrophenyl-β-D-glucopyranoside and 0.1 ml of enzyme to 0.3 ml of 0.1 M sodium phosphate buffer (pH 7.0) After reacting for 30 minutes, 0.3 ml of 0.5 N NaOH was added to terminate the reaction. The absorbance at 405 nm was then measured using a supernatant centrifuged (13,000 rpm, 5 min).
베타글루쿠로니데이즈(β-Glucuronidase) 억제 활성 측정은 0.1M Sodium phosphate buffer(pH7.0) 0.38ml에 2mM pnitrophenyl-βD-glucuronide 0.02ml과 효소액 0.1ml을 첨가하여 37℃ shaking water bath에서 30분간 반응시킨 후, 0.5N NaOH를 0.4ml 첨가하여 반응을 종료시켰다. 이후 원심분리(13,000rpm, 5min)한 상등액을 이용하여 405 nm에서 흡광도를 측정하였다. The inhibitory activity of β-glucuronidase was determined by adding 0.02 ml of 2 mM pnitrophenyl-β-D-glucuronide and 0.1 ml of enzyme solution to 0.38 ml of 0.1 M sodium phosphate buffer (pH 7.0) and incubating the cells in a shaking water bath at 37 ° C. for 30 minutes After the reaction, 0.4 ml of 0.5 N NaOH was added to terminate the reaction. The absorbance at 405 nm was then measured by centrifugation (13,000 rpm, 5 min).
트립토파네이즈(Tryptophanase) 억제 활성 측정은 반응 혼합액(0.05N potassium phosphate(pH7.5) 22.5ml, pyridoxal phosphate 2.75mg, disodium EDTA dehydrate 19.6mg, bovine serum albumin 10mg, distilled water 87.5ml) 0.2ml에 0.02M tryptophan 0.2ml 및 효소액 0.1ml를 첨가하여 37℃ Shaking water bath에서 30분 반응시키고 발색시약(95% EtOH 94.8ml, 36N H2SO4 5.2ml, ρ-diaminobenzaldehyde 14.7g)을 2ml를 첨가하여 반응을 종료시킨 후 원심분리(13,000rpm, 5min)한 상등액을 이용하여 550nm에서 흡광도를 측정하였다.The inhibitory activity of tryptophanase was determined by adding 0.02 to 0.2 ml of a reaction mixture (22.5 ml of 0.05 N potassium phosphate (pH 7.5), 2.75 mg of pyridoxal phosphate, 19.6 mg of disodium EDTA dehydrate, 10 mg of bovine serum albumin, and 87.5 ml of distilled water) M tryptophan and 0.1 ml of the enzyme solution were reacted in a shaking water bath at 37 ° C for 30 minutes, and 2 ml of a coloring reagent (94.8 ml of 95% EtOH, 5.2 ml of 36N H 2 SO 4 and 14.7 g of ρ-diaminobenzaldehyde) And the absorbance at 550 nm was measured using a supernatant centrifuged (13,000 rpm, 5 min).
도 2(2a,2b,2c)에 나타낸 바와 같이, 락토바실러스 람노서스 GG(LGG) 균주를 포함한 분리균주 중에서 L54, L67, L83 및 L120 균주에서 베타글루코시데이즈(β-Glucosidase), 베타글루쿠로니데이즈(β-Glucuronidase) 및 트립토파네이즈(Tryptophanase)의 효소 활성억제 효과가 높게 측정되었고, 특히 L54 균주에서 장내유해효소들의 활성억제 효과가 가장 높게 측정되었다. 따라서 장내유해효소 활성억제 효과가 우수한 L54 균주는 효과적으로 장내환경을 개선할 수 있을 것으로 판단된다.As shown in Fig. 2 (2a, 2b, 2c), among the isolated strains containing Lactobacillus lambatus GG (LGG) strains, beta-glucosidase, beta-glucosidase Β-Glucuronidase and Tryptophanase were found to be highly effective in inhibiting the enzyme activity. In particular, L54 strain was found to have the highest inhibitory effect on intestinal harmful enzymes. Therefore, L54 strain, which has excellent inhibitory effect on intestinal toxic enzyme activity, can be effectively improved intestinal environment.
1-6. 16S rRNA 유전자 염기서열 분석을 통한 유산규 동정1-6. 16S rRNA Gene Sequence Analysis
환경스트레스에 대한 저항성이 우수한 균주로 최종 선정된 L3, L54 및 L120 균주의 동정을 위하여 16S rRNA 유전자 염기서열 분석을 수행하였다. 구체적으로 AccuPrepR Genomic DNA Extraction kit (Bioneer, Daejeon, Korea)를 이용하여 균주의 genomic DNA를 분리하였고, 27F(5'-AGA GTT TGA TCM TGG CTC AG-3'), 1492R (5'-TAC GGY TAC CTT GTT ACG ACTT-3') primer를 사용하여 polymerase chain reaction (PCR)을 수행하였다. PCR은 Accu-PrepR PreMix (Bioneer)를 사용하여 My Cycler (BIO-RAD Laboratories, Hercules, CA, USA)로 반응시켰으며, PCR 조건은 94℃에서 2분, 1 cycle; 94℃에서 30초, 60℃에서 1분, 72℃에서 1분, 35 cycle; 72℃에서 7분간 반응시켰다. PCR 산물의 염기서열 결정은 Macrogen사(Seoul, Korea)에 의뢰하여 ABI PRISM 3700 DNA Analyzer를 이용하여 수행하였다. 16S rRNA gene sequencing was performed to identify L3, L54, and L120 strains that were selected as strains resistant to environmental stress. The genomic DNA of the strain was isolated using AccuPrep® Genomic DNA Extraction kit (Bioneer, Daejeon, Korea), and 27F (5'-AGA GTT TGA TCM TGG CTC AG-3 ') and 1492R (5'-TAC GGY TAC CTT GTT ACG ACTT-3 ') polymerase chain reaction (PCR). PCR was performed with My Cycler (BIO-RAD Laboratories, Hercules, Calif., USA) using Accu-PrepR PreMix (Bioneer). 30 sec at 94 占 폚, 1 min at 60 占 폚, 1 min at 72 占 폚, 35 cycles; Followed by reaction at 72 ° C for 7 minutes. The nucleotide sequence of the PCR product was determined using an ABI PRISM 3700 DNA Analyzer (Macrogen, Seoul, Korea).
또한, 상기 분리한 균주의 염기서열은 NCBI(National Center for Biotechnology Information: 미국 국립생물정보센터)에서 BLAST를 이용하여 미생물 상동성을 분석하였다. In addition, the nucleotide sequence of the isolated strain was analyzed by microbial homology using BLAST at National Center for Biotechnology Information (NCBI).
하기 표 3에 나타낸 바와 같이, 분리균주의 동정을 위하여 16S rRNA 유전자 염기서열 분석을 수행한 결과, L3 균주는 락토바실러스 람노서스와 99% 이상의 유사도를 나타내었으며, L54 균주는 엔테로코커스 패시움과 99% 이상의 유사도를 나타내었고, L120 균주는 락토바실러스 애시도필러스와 99% 이상의 유사도를 나타내었다. 따라서 최종적으로 L3 균주는 락토바실러스 람노서스 L3, L54 균주는 엔테로코커스 패시움 L54, L120 균주는 락토바실러스 애시도필러스 L120으로 명명하였다.As shown in Table 3 below, 16S rRNA gene sequencing analysis was performed to identify the isolates. As a result, L3 strain showed 99% or more similarity with Lactobacillus lambusus, L54 strain had 99% %, And the strain L120 showed 99% or more similarity with Lactobacillus acidophilus. Finally, the L3 strain was named Lactobacillus laminocus L3, the L54 strain was named Enterococcus lassi L54, and the L120 strain was named Lactobacillus aspirophilus L120.
<동작설명 2> 프로바이오틱스로서 이용 가능성 탐색<Explanation of operation 2> Exploring availability as probiotics
유산균이 프로바이오틱스로 정장작용의 효능을 발휘하기 위해서는 생체 내에서 생존할 수 있는 능력이 중요하며, 이를 위해서는 강산성의 위액 및 췌장과 십이지장에서 분비되는 담즙액을 통과하여 생존해야 한다. 따라서 상기 <동작설명 1>에서 분리한 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54 및 락토바실러스 애시도필러스 L120 균주들의 장내생존 가능성을 확인하기 위하여 상기 분리균주들의 인공위액 및 인공담즙 저항성 시험을 각각 pH 2.5로 조절된 배지와 담즙(oxgall)이 0.5%, 1.0% 함유된 배지를 이용하여 수행하였다.In order for lactobacilli to exert their effects in a probiotic process, their ability to survive in vivo is important and must survive through strong acidic gastric juices and bile fluid secreted from the pancreas and duodenum. Therefore, in order to confirm the survival possibility of Lactobacillus laminosus L3, Enterococcus lassus L54 and Lactobacillus acidophilus L120 strains isolated in <Description of Action 1> described above, the artificial gastric juice and artificial bile resistance test Were carried out using a medium adjusted to pH 2.5 and a medium containing 0.5% and 1.0% of oxgall.
구체적으로 인공위액 저항성 실험은 체내 소화관 조건과 유사한 환경에서 측정하기 위하여 1N HCl을 사용하여 pH 2.5로 조정한 MRS 액체배지에 pepsin(Sigma Co., USA) 1,000units/ml를 첨가한 후 유산균주를 접종하여 37℃에서 2시간 동안 배양하였다. 배양액을 MRS 고체배지에 도말하여 37℃에서 48시간 동안 혐기배양한 후 생성된 콜로니 수를 측정하였고 Log CFU(colony forming unit)/mL로 표시하였다. 이때 생존율(%)은 [(실험구의 Log 지수값/대조구의 Log 지수값)×100]로 나타내었으며, 대조구는 인공위액 무처리구로 설정하였다. Specifically, the artificial gastric juice resistance test was carried out by adding 1,000 units / ml of pepsin (Sigma Co., USA) to the MRS liquid medium adjusted to pH 2.5 using 1N HCl in an environment similar to that of the digestive tract of the body, And inoculated and cultured at 37 ° C for 2 hours. The cultures were plated on MRS solid medium and anaerobically cultured at 37 ° C for 48 hours. The number of colonies formed was measured and expressed as Log CFU (colony forming unit) / mL. Survival rate (%) was expressed as [(Log index value of experimental group / Log index value of control group) × 100], and control group was set as control group for artificial gastric juice.
또한 인공담즙 저항성 실험은 인공위액 저항성 시험을 거친 배양액을 oxgall(Sigma Co., USA)이 각각 0.5%, 1.0% 첨가된 MRS 액체배지에 첨가하여 37℃에서 24시간 동안 배양하였다. 배양액을 MRS 고체배지에 도말하여 37℃에서 48시간 동안 혐기배양한 후 생성된 콜로니 수를 측정하였고 Log CFU(colony forming unit)/mL로 표시하였다. 이때 생존율(%)은 [(실험구의 Log 지수값/대조구의 Log 지수값)×100]로 나타내었으며, 대조구는 인공담즙 무처리구로 설정하였다. In addition, the artificial gastric juice resistance test was carried out at 37 ° C for 24 hours after addition of 0.5% and 1.0% of oxgall (Sigma Co., USA) to the MRS broth. The cultures were plated on MRS solid medium and anaerobically cultured at 37 ° C for 48 hours. The number of colonies formed was measured and expressed as Log CFU (colony forming unit) / mL. Survival rate (%) was expressed as [(Log index value of experimental group / log index value of control group) × 100], and the control group was set as an artificial bile control group.
도 3에 나타낸 바와 같이, 인공위액 저항성 실험에서 락토바실러스 람노서스 L3 균주, 엔테로코커스 패시움 L54 균주 및 락토바실러스 애시도필러스 L120 균주는 락토바실러스 람노서스 GG(LGG) 균주와 유사하게 83%의 높은 생존율을 나타내었다. 3, Lactobacillus laminosus L3 strain, Enterococcus lassus L54 strain and Lactobacillus acidophilus strain L120 strain were found to have an 83% (v / v) similarity to Lactobacillus lambosus GG And high survival rate.
또한 인공담즙 저항성 실험에서 락토바실러스 람노서스 L3 균주, 엔테로코커스 패시움 L54 균주 및 락토바실러스 애시도필러스 L120 균주는 락토바실러스 람노서스 GG(LGG) 균주와 유사하게 장내 담즙농도 보다 고농도인 0.5% oxgall과 1.0% oxgall에서 각각 87%, 57%의 높은 생존율을 나타내었다. 따라서 본 연구를 통하여 분리된 균주는 인공위액에서 생존이 가능하고 동시에 담즙에 대한 높은 저항성을 나타내어 장내 생존가능성이 매우 우수하므로 프로바이오틱스로서 활용될 수 있는 가능성을 확인할 수 있었다.Lactobacillus Lymphosus L3 strain, Enterococcus lassus L54 strain, and Lactobacillus acidophilus strain L120 were found to have a high concentration of 0.5% oxgall in the intestinal bile test, similar to Lactobacillus lymphosus GG (LGG) And 1.0% oxgall showed high survival rates of 87% and 57%, respectively. Therefore, the isolated strains were able to survive in the artificial gastric juice and exhibit high resistance to bile, and thus have a high possibility of survival in the intestines. Therefore, it is possible to utilize them as probiotics.
<동작설명 3> 발효유 제조<Description of
3-1. 발효유 제조용 스타터 균 제조3-1. Manufacture of starter bacteria for the production of fermented milk
발효유 제조용 스타터 균 제조는 환경스트레스에 대한 저항성이 우수한 인체유래유산균 3종 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54, 락토바실러스 애시도필러스 L120과 상업균주 Chr. Hansen사의 YF-L812 (Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus)를 각각 10mL MRS 액체배지에 원유 및 설탕 혼합물에 대한 0.8-1.2 중량부, 바람직하게 1% (원유 및 설탕 혼합물의 1 중량부)접종하여 37℃에서 24시간 동안 정치배양 하였다. 배양액은 원심분리하여 상등액을 제거한 다음 남은 균체를 멸균된 생리식염수에 현탁시켜 세척한 후 10%의 멸균탈지유에 2회 종균 배양하여 사용하였다.Lactobacillus Lymphosus L3, Enterococcus lassus L54, Lactobacillus acidophilus L120, and commercial strains Chr. And 0.8 to 1.2 parts by weight of the Hansen's YF-L812 (Lactobacillus delbrueckii subsp. Bulgaricus, Streptococcus thermophilus) in each oil and sugar mixture to 10mL MRS broth, (1 part by weight of oil and sugar mixture), preferably 1% inoculation Followed by constant culture at 37 占 폚 for 24 hours. After the supernatant was removed by centrifugation, the remaining cells were suspended in sterilized physiological saline, washed, and cultured in 10% sterilized skim milk twice.
3-2. 스타터 첨가 비율에 따른 발효유 제조 방법3-2. Production method of fermented milk according to starter addition ratio
발효유의 제조는 원유 1000g에 정백당 바람직하게 50g (원유의 4-6 중량부중에서)을 첨가하여 혼합한 후 90℃에서 10분간 살균하고, 43℃에서 냉각하였다. In the preparation of the fermented milk, 50 g (in 4-6 parts by weight of crude oil) was preferably added to 1000 g of crude oil, and the mixture was sterilized at 90 캜 for 10 minutes and cooled at 43 캜.
이후 상업균주(YF-L812)(A)와 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54 및 락토바실러스 애시도필러스 L120 균주가 각각 1:1:1의 비율로 혼합된 혼합균주(B)를 원유와 설탕의 혼합물 100 중량부에 대하여 0.8-1.2 중량부이며, 바람직하게 하나의 예로써 1 중량부 (1%)로써,Thereafter, a mixed strain (B) in which commercial strains (YF-L812) (A), Lactobacillus lambosus L3, Enterococcus pathum L54, and Lactobacillus acidophilus L120 strains were mixed at a ratio of 1: 0.8-1.2 parts by weight based on 100 parts by weight of a mixture of crude oil and sugar, and preferably 1 part by weight (1%) as an example,
각각 1.0%:0.0%, 0.8%:0.2g%, 0.6g:0.4g, 0.4g:0.6g, 0.2g:0.8g, 0.1g:0.9g 또는 0.0:1.0% 비율로 바람직하게 1% (0.8-1.2중에서) 접종하여 42℃에서 pH가 4.6이 될 때까지 6~8시간 동안 배양하였다. pH가 4.6에 도달한 각각의 발효유는 이후 15℃까지 냉각하고 4℃에서 냉장보관하면서 숙성시켰다. 발효유 제조공정은 도 4와 같다.(0.8%) in a proportion of 1.0%: 0.0%, 0.8%: 0.2g%, 0.6g: 0.4g, 0.4g: 0.6g, 0.2g: 0.8g, 0.1g: 0.9g or 0.0: -1.2) and incubated for 6-8 hours at 42 [deg.] C until the pH reached 4.6. Each fermented milk having a pH of 4.6 was then aged while cooling to 15 ° C and refrigerated at 4 ° C. The fermented milk production process is shown in Fig.
한편, 본 발명을 설명함에 있어서, 원유라 함은, 발효유 제조를 위해 홀스타인 프리지안(Holstein-Friesian)종에서 생산된 산도가 0.14 ~ 0.15%이고, pH가 6.6 ~ 6.8 범위인 신선한 원유를 말한다.In the description of the present invention, the raw material refers to fresh crude oil having an acidity of 0.14 to 0.15% and a pH of 6.6 to 6.8 produced from Holstein-Friesian species for producing fermented milk.
3-3. 발효유 제조과정 중 품질특성3-3. Quality characteristics during fermented milk manufacturing process
발효유 제조과정 중 발효시간에 따른 pH, 적정산도 및 유산균수의 변화를 측정하였다. 구체적으로 pH 측정은 pH meter(UB-10, Denver, USA)를 이용하였으며, 적정산도는 시료 10mL에 증류수 10mL를 혼합하여 현탁액을 만든 후 이 현탁액을 NaOH를 첨가하여 pH 8.3까지 적정하고 NaOH의 소비량에 유산의 환산계수인 0.9를 곱한 후 검체의 무게(g)를 나누어 나타낸 값을 적정산도(%)로 하였다. 유산균수의 변화는 시료 1mL를 채취하여 멸균식염수에 십진 희석법으로 희석한 뒤 BCP 한천배지를 이용하여 평판배양법으로 37℃에서 48시간 동안 배양하였다. 그 후 나타난 노랑색 콜로니 수를 측정하여 Log CFU(colony forming unit)/mL로 표시하였다.Changes in pH, titratable acidity and number of lactic acid bacteria were measured during the fermentation process. Specifically, a pH meter (UB-10, Denver, USA) was used for pH measurement. 10 mL of sample was mixed with 10 mL of distilled water to prepare a suspension. The suspension was titrated to pH 8.3 by adding NaOH, Was multiplied by the conversion factor of 0.9 of lactic acid, and the weight (g) of the sample was divided to obtain the titratable acidity (%). The change in the number of lactic acid bacteria was obtained by taking 1 mL of the sample, diluting it in sterilized saline by decidual dilution method, and culturing it at 37 ° C for 48 hours in a plate culture method using BCP agar medium. The number of yellow colonies after that was measured and expressed as Log CFU (colony forming unit) / mL.
하기 표 4에 나타낸 바와 같이, 인체유래유산균 3종 혼합균주와 상업균주(YF-L812)를 첨가비율을 달리하여 제조한 발효유의 발효시간에 따른 pH, 적정산도 및 유산균수의 변화를 확인한 결과 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54, 락토바실러스 애시도필러스 L120 3종의 혼합균주로만 발효시킨 발효유는 산 생성력이 낮아 발효유 제조용 스타터로서 적합하지 않았다. 그러나 상업균주(YF-L812)와 인체유래유산균 3종 혼합균주를 각각 0.8%:0.2g%, 0.6g:0.4g, 0.4g:0.6g, 0.2g:0.8g, 0.1g:0.9g의 비율로 혼합하여 제조한 발효유의 경우는 상업균주를 단독으로 사용하여 제조한 발효유와 유사하게 발효 6시간째 발효 종말점인 pH 4.6에 도달하였다. 또한 적정산도는 0.85~0.91%를 유지하였으며, 유산균수는 109 CFU/mL을 유지하였다. 따라서 환경스트레스에 대한 저항성이 우수한 발효유 제조용 유산균 스타터를 개발하기 위해서는 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54, 락토바실러스 애시도필러스 L120 3종의 혼합균주와 산 생성력이 우수한 유산균을 혼합하여 사용하는 것이 적합할 것으로 판단되며, 추후 상업적으로도 활용 가능성이 높을 것이다.As shown in the following Table 4, changes in pH, titratable acidity and number of lactic acid bacteria of fermented milk prepared by varying the addition ratio of three kinds of lactic acid bacteria derived from human body and commercial strains (YF-L812) Bacillus lambatus L3, Enterococcus lassus L54, Lactobacillus acidophilus L120 Fermented milk fermented only as a mixture of three strains was not suitable as a starter for fermented milk production due to its low acid production ability. However, the commercial strains (YF-L812) and the mixed strains of three kinds of human-derived lactic acid bacteria were mixed at a ratio of 0.8%: 0.2g%, 0.6g: 0.4g, 0.4g: 0.6g, 0.2g: 0.8g, , The fermented milk reached pH 4.6, the end point of fermentation at 6 hours after fermentation, similar to fermented milk prepared by using the commercial strain alone. The titratable acidity was maintained at 0.85 ~ 0.91% and the number of lactic acid bacteria was maintained at 10 9 CFU / mL. Therefore, in order to develop a lactic acid bacteria starter for producing fermented milk having excellent resistance to environmental stress, a mixed strain of Lactobacillus laminosus L3, Enterococcus lassus L54, and Lactobacillus acidophilus L120 is mixed with lactic acid bacteria having excellent acid producing ability And it is likely to be used commercially in the future.
pH
pH
적정산도
(%)
Titratable acidity
(%)
유산균수
(log CFU/㎖)
Number of lactic acid bacteria
(log CFU / ml)
YF : YF-L812 (Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus) YF: YF-L812 (Lactobacillus delbrueckii subsp bulgaricus, Streptococcus thermophilus.)
Mix : Lactobacillus rhamnosus L3, Enterococcus faecium L54, Lactobacillus acidophilus L120Mix: Lactobacillus rhamnosus L3 , Enterococcus faecium L54, Lactobacillus acidophilus L120
3-4. 발효유 관능평가3-4. Sensory evaluation of fermented milk
발효유의 관능적 특성을 평가하기 위해 연구소의 숙련된 관능평가요원 10명을 관능평가 패널로 선정하였다. 패널에게 실험목적을 설명하고 각 측정치에 대해 교육시킨 뒤 9점 척도 법을 사용하며 색, 향, 맛, 조직감 및 전체 기호도에 대한 검사를 실시한 후 모든 측정값은 평균±표준편차로 표시하였다. In order to evaluate the sensory characteristics of fermented milk, 10 sensory evaluation personnel of the institute were selected as the sensory evaluation panel. The panel explained the purpose of the experiment and educated about each measurement. Then, 9 point scale method was used and color, flavor, taste, texture, and overall acceptability were measured. All measurements were expressed as mean ± standard deviation.
아래 표 5에 나타낸 바와 같이, 환경스트레스에 대한 저항성이 우수한 인체유래유산균 3종 을 이용하여 제조한 발효유의 관능검사를 실시한 결과 상업균주(YF-L812)를 단독으로 사용하여 제조한 발효유와, 상업균주(YF-L812)와 인체유래유산균 3종의 첨가량을 달리하여 제조한 발효유 및 상업균주(YF-L812) 첨가없이 인체유래유산균 3종을 혼합하여 제조한 발효유 모두 색, 맛, 조직감 항목에서 크게 차이를 나타내지 않았다. 그러나 향 항목에서는 락토바실러스 불가리쿠스, 스트렙토코커스 써모필러스, 락토바실러스 람노서스, 엔테로코커스 패시움 및 락토바실러스 애시도필러스 유산균 5종이 포함된 상업균주(YF-L812)와 인체유래유산균 3종 혼합 발효유에서 높은 기호도를 나타냈으며, 특히 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54 및 락토바실러스 애시도필러스 L120 혼합균주 첨가량이 증가할수록 향에 대한 기호도가 상승함에 따라 전반적인 기호도가 증가하는 것을 확인할 수 있었다. As shown in Table 5 below, the fermented milk produced from three kinds of human-derived lactic acid bacteria having excellent resistance to environmental stress was subjected to sensory evaluation. As a result, fermented milk prepared by using the commercial strain (YF-L812) (YF-L812) and fermented milk prepared by mixing three kinds of human-derived lactic acid bacteria without addition of commercial fermented milk and commercial strain (YF-L812) Did not show any difference. However, a commercial strain (YF-L812) containing 5 kinds of Lactobacillus bulgaricus, Streptococcus thermophilus, Lactobacillus laminosus, Enterococcus pathum and Lactobacillus acidophilus lactic acid bacteria and a mixture of three kinds of human-derived lactic acid bacteria Fermented milk showed a high preference. Especially, it was confirmed that the overall preference was increased as the degree of preference for the flavor increased as the amount of Lactobacillus laminosus L3, Enterococcus lassus L54, and Lactobacillus acidophilus L150 was increased there was.
따라서 환경스트레스에 대한 저항성이 우수한 발효유를 제조하기 위한 유산균 스타터 첨가량은 상업균주(YF-L812)와 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54, 락토바실러스 애시도필러스 L120 3종 혼합균주의 0.1%:0.9% 혼합비율(1:9)이 가장 적합할 것으로 사료된다.Therefore, the addition amount of the lactic acid bacteria starter to produce the fermented milk having excellent resistance to environmental stress is 0.1 to 10 times that of the commercial strain (YF-L812), Lactobacillus laminosus L3, Enterococcus lassi L54, and Lactobacillus acidophilus L120 %: 0.9% mixture ratio (1: 9) would be most suitable.
YF : YF-L812 (Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus) YF: YF-L812 (Lactobacillus delbrueckii subsp bulgaricus, Streptococcus thermophilus.)
Mix : Lactobacillus rhamnosus L3, Enterococcus faecium L54, Lactobacillus acidophilus L120Mix: Lactobacillus rhamnosus L3 , Enterococcus faecium L54, Lactobacillus acidophilus L120
본 발명의 기술적 사상은 다음과 같다.The technical idea of the present invention is as follows.
상기한 바의 방법에 의거, 아래 3개의 균주를 신규 분리한다.According to the method described above, the following three strains are newly isolated.
락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54 및 락토바실러스 애시도필러스 L120 균주.Lactobacillus Lymphosus L3, Enterococcus pathum L54, and Lactobacillus acidophilus L120.
상기 신규 분리한 균주와 상업적 균주 2개를 사용하여 접종을 통해 발효유를 제조하는 것이다.And the fermented milk is produced by inoculation using the newly isolated strain and two commercial strains.
세부 동작으로는, 발효유 제조방법에 있어서,As a detailed operation, in the fermented milk production method,
원유, 설탕을 혼합하여 제 1 혼합물을 제조하는 단계;Mixing crude oil and sugar to produce a first mixture;
상기 제 1 혼합물을 살균하는 단계;Sterilizing the first mixture;
상기 살균된 제 1 혼합물을 냉각하는 단계;Cooling the sterilized first mixture;
상기 냉각된 제 1 혼합물에 스타터로 프로바이오틱스 유산균을 접종하는 단계;Inoculating the cooled first mixture with probiotic lactic acid bacteria as a starter;
상기 스타터로 프로바이오틱스 유산균이 접종된 제 2 혼합물을 배양하는 단계;Culturing a second mixture in which the probiotic lactic acid bacteria has been inoculated with the starter;
상기 배양된 제 2 혼합물을 냉각하는 단계; 및Cooling the cultured second mixture; And
상기 유산균이 배양되어 냉각된 제 2 혼합물을 냉장저장하는 단계;를 포함하여 이루어지는 것을 특징으로 하는 환경스트레스에 저항성이 우수한 인체유래유산균을 이용한 발효유의 제조한다.And fermenting the fermented milk using the lactic acid bacterium derived from human body, which is excellent in resistance to environmental stress.
또한 원유 및 설탕과, 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54 및 락토바실러스 애시도필러스 L120 균주와 락토바실러스 불가리쿠스 및 스트렙토코커스 써모필러스 균주를 준비하는 준비단계;Preparing a crude oil and sugar, Lactobacillus lambosus L3, Enterococcus lassi L54 and Lactobacillus acidophilus L120, Lactobacillus bulgaricus and Streptococcus thermophilus strain;
상기 준비단계에서 준비한 원유 100중량부에 대하여 설탕 4~6중량부, 바람직하게는 5 중량부 (원유를 기준으로 5%)를 혼합하여 제 1 혼합물을 제조하는 혼합단계; Mixing 4 to 6 parts by weight, preferably 5 parts by weight (5% based on crude oil) of sugar with respect to 100 parts by weight of the crude oil prepared in the preparation step to prepare a first mixture;
상기 제 1 혼합물을 85~95℃의 온도로 5~15분간 살균하는 살균단계; Sterilizing the first mixture at a temperature of 85 to 95 DEG C for 5 to 15 minutes;
상기 살균된 제 1 혼합물을 40~45℃로 냉각시키는 냉각단계; Cooling the sterilized first mixture to 40 to 45 캜;
상기 냉각된 제 1 혼합물 100중량부에 대하여 스타터로 유산균 0.8-1.2중량부를 접종하는 접종단계; An inoculation step of inoculating 0.8-1.2 parts by weight of lactic acid bacteria as a starter with respect to 100 parts by weight of the cooled first mixture;
상기 스타터로 유산균이 접종된 제 2 혼합물을 최종 pH가 4.3~4.6이 될 때까지 35~45℃의 온도로 6~8시간 동안 발효시켜 발효유를 만드는 발효단계; Fermenting the fermented milk by fermenting the second mixture in which lactic acid bacteria have been inoculated with the starter at a temperature of 35 to 45 캜 for 6 to 8 hours until the final pH is 4.3 to 4.6;
상기 발효된 발효유를 15~20℃로 냉각시키는 발효유 냉각단계; 및Cooling the fermented milk to 15 to 20 캜; And
상기 냉각된 발효유를 3~5℃의 온도로 냉장저장하는 냉장단계: 를 포함하는 것을 특징으로 하는 환경스트레스 저항성이 우수한 인체유래유산균을 이용한 발효유를 제조한다.And cooling the cooled fermented milk at a temperature of 3 to 5 DEG C to produce fermented milk using the human lactic acid bacteria having excellent environmental stress resistance.
상기 접종되는 유산균은 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54, 락토바실러스 애시도필러스 L120, 락토바실러스 불가리쿠스 및 스트렙토코커스 써모필러스로 구성된다.The inoculated lactic acid bacteria are composed of Lactobacillus laminosus L3, Enterococcus lassus L54, Lactobacillus acidophilus L120, Lactobacillus bulgaricus, and Streptococcus thermophilus.
상기 접종되는 유산균은 원유 및 설탕의 혼합믈 100중량부에 대하여 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54, 락토바실러스 애시도필러스 L120 혼합균(A)와, 락토바실러스 불가리쿠스와 스트렙토코커스 써모필러스의 혼합균(B를) 0.8-1.2중량부 접종하며, 상기 A와 B는 9:1 비율로 접종한다.The inoculated lactic acid bacterium was prepared by mixing 100 parts by weight of a mixture of crude oil and sugar with a mixture of Lactobacillus laminosus L3, Enterococcus lassus L54, Lactobacillus acidophilus L120 mixed bacterium (A), Lactobacillus bulgaricus and Streptococcus thermo 0.8-1.2 parts by weight of the mixed microorganism (B) of Phyllis is inoculated, and the above A and B are inoculated at a ratio of 9: 1.
상기에서 락토바실러스 람노서스 L3 100 중량부에 대하여, 엔테로코커스 패시움 L54 100 중량부 및 락토바실러스 애시도필러스 L120 100 중량부로 구성된다.100 parts by weight of Lactobacillus laminocus L3 is composed of 100 parts by weight of Enterococcus passum L54 and 100 parts by weight of Lactobacillus acidophilus L120.
상기한 바와 같이 본 발명은 환경 스트레스에 저항성이 우수한 인체유래유산균 및 이를 이용한 발효유의 제조방법에 관한 것으로써, 성인분변으로부터 분리되고, 산화적 스트레스, 중금속 및 방사선 저항성이 우수하며, 장내유해효소 억제 활성을 가지고, 프로바이오틱스 유산균이 되기 위하여 인공위액 및 인공담즙액 저항성이 우수한 락토바실러스 람노서스 L3, 엔테로코커스 패시움 L54 및 락토바실러스 애시도필러스 L120 균주등을 함유하는 기능성 발효유의 제조방법에 관한 것이다. As described above, the present invention relates to a human-derived lactic acid bacterium having excellent resistance to environmental stress, and a method for producing fermented milk using the same, wherein the human lactic acid bacterium is isolated from adult feces and has excellent oxidative stress, heavy metals and radiation resistance, Lactobacillus lambatus L3, Enterococcus lassus L54 and Lactobacillus acidophilus strain L120, which are excellent in artificial gastric juice and artificial bile fluid resistance to be probiotic lactic acid bacteria, and the like, .
Claims (6)
원유, 설탕을 혼합하여 제 1 혼합물을 제조하는 단계;
상기 제 1 혼합물을 살균하는 단계;
상기 살균된 제 1 혼합물을 냉각하는 단계;
상기 냉각된 제 1 혼합물에 스타터로 프로바이오틱스 유산균을 접종하는 단계;
상기 스타터로 프로바이오틱스 유산균이 접종된 제 2 혼합물을 배양하는 단계;
상기 배양된 제 2 혼합물을 냉각하는 단계; 및
상기 유산균이 배양되어 냉각된 제 2 혼합물을 냉장저장하는 단계;를 포함하고, 상기 접종되는 유산균은 락토바실러스 람노서스 L3기탁번호 KCTC18485P, 엔테로코커스 패시움 L54기탁번호 KCTC18486P, 락토바실러스 애시도필러스 L120기탁번호 KCTC18487P, 락토바실러스 불가리쿠스 및 스트렙토코커스 써모필러스로 구성되는 것을 특징으로 하는 환경스트레스 저항성이 우수한 인체유래유산균을 이용한 발효유의 제조방법.A method for producing a fermented milk,
Mixing crude oil and sugar to produce a first mixture;
Sterilizing the first mixture;
Cooling the sterilized first mixture;
Inoculating the cooled first mixture with probiotic lactic acid bacteria as a starter;
Culturing a second mixture in which the probiotic lactic acid bacteria has been inoculated with the starter;
Cooling the cultured second mixture; And
Wherein the inoculated lactic acid bacterium is selected from the group consisting of Lactobacillus laminosus L3 deposit number KCTC18485P, Enterococcus pathum L54 deposit number KCTC18486P, Lactobacillus acidophilus L120 A lactic acid bacteria belonging to the genus Lactobacillus, a lactic acid bacteria belonging to the genus Lactobacillus, a lactic acid bacteria belonging to the genus Lactobacillus, and a Streptococcus thermophilus.
상기 준비단계에서 준비한 원유 100중량부에 대하여 설탕 4~6중량부를 혼합하여 제 1 혼합물을 제조하는 혼합단계;
상기 제 1 혼합물을 85~95℃의 온도로 5~15분간 살균하는 살균단계;
상기 살균된 제 1 혼합물을 40~45℃로 냉각시키는 냉각단계;
상기 냉각된 제 1 혼합물 100중량부에 대하여 스타터로 유산균 0.8-1.2중량부를 접종하는 접종단계;
상기 스타터로 유산균 0.8-1.2 중량부가 접종된 제 2 혼합물을 최종 pH가 4.3~4.6이 될 때까지 35~45℃의 온도로 6~8시간 동안 발효시켜 발효유를 만드는 발효단계;
상기 발효된 발효유를 15~20℃로 냉각시키는 발효유 냉각단계; 및
상기 냉각된 발효유를 3~5℃의 온도로 냉장저장하는 냉장단계: 를 포함하는 것을 특징으로 하는 환경스트레스 저항성이 우수한 인체유래유산균을 이용한 발효유의 제조방법.
Crude oil and sugar, Lactobacillus Lymphosus L3 Accession No. KCTC18485P, Enterococcus lassi L54 Accession No. KCTC18486P and Lactobacillus acidophilus L120 Accession No. KCTC18487P strain, Lactobacillus bulgaricus and Streptococcus thermophilus strain step;
Mixing 4 to 6 parts by weight of sugar with 100 parts by weight of crude oil prepared in the preparation step to prepare a first mixture;
Sterilizing the first mixture at a temperature of 85 to 95 DEG C for 5 to 15 minutes;
Cooling the sterilized first mixture to 40 to 45 캜;
An inoculation step of inoculating 0.8-1.2 parts by weight of lactic acid bacteria as a starter with respect to 100 parts by weight of the cooled first mixture;
Fermenting the fermented milk by fermenting the second mixture inoculated with 0.8-1.2 parts by weight of lactic acid bacteria with the starter at a temperature of 35 to 45 ° C for 6 to 8 hours until the final pH is 4.3 to 4.6;
Cooling the fermented milk to 15 to 20 캜; And
And cooling the cooled fermented milk at a temperature of 3 to 5 占 폚. The method for producing fermented milk using the human-derived lactic acid bacterium according to claim 1,
상기 접종되는 유산균은 원유 및 설탕의 혼합믈 100중량부에 대하여 락토바실러스 람노서스 L3기탁번호 KCTC18485P, 엔테로코커스 패시움 L54기탁번호 KCTC18486P, 락토바실러스 애시도필러스 L120기탁번호 KCTC18487P 혼합균(A)와, 락토바실러스 불가리쿠스와 스트렙토코커스 써모필러스의 혼합균(B를) 0.8-1.2중량부 접종하며, 상기 A와 B는 9:1 비율로 접종하는 것을 특징으로 하는 환경스트레스 저항성이 우수한 인체유래유산균을 이용한 발효유의 제조방법
3. The method according to claim 1 or 2,
The inoculated lactic acid bacteria were mixed with 100 parts by weight of a mixture of crude oil and sugar with 100 parts by weight of lactobacillus laminosis L3 deposit number KCTC18485P, enterococcus pathum L54 deposit number KCTC18486P, Lactobacillus acidophilus L120 deposit number KCTC18487P mixed bacteria (A) , 0.8-1.2 parts by weight of a mixed microorganism (B) of Lactobacillus bulgaricus and Streptococcus thermophilus, and said A and B are inoculated at a ratio of 9: 1. For the production of fermented milk using
락토바실러스 람노서스 L3기탁번호 KCTC18485P 100 중량부에 대하여, 엔테로코커스 패시움 L54기탁번호 KCTC18486P 100 중량부 및 락토바실러스 애시도필러스 L120기탁번호 KCTC18487P 100 중량부로 구성되는 것을 특징으로 하는 환경스트레스 저항성이 우수한 인체유래유산균을 이용한 발효유의 제조방법.5. The method of claim 4,
100 parts by weight of Enterococcus pathum L54 deposit number KCTC18486P and 100 parts by weight of Lactobacillus acidophilus L120 deposit number KCTC18487P relative to 100 parts by weight of Lactobacillus laminocus L3 deposit number KCTC18485P. A method for producing fermented milk using lactic acid bacteria derived from human body.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160078322 | 2016-06-23 | ||
KR20160078322 | 2016-06-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20180000657A KR20180000657A (en) | 2018-01-03 |
KR101941645B1 true KR101941645B1 (en) | 2019-04-11 |
Family
ID=61002415
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160109879A KR101941645B1 (en) | 2016-06-23 | 2016-08-29 | Lactic acid bacteria strains derived from human body with excellent resistance to environmental stress and Method for producing yogurt using it |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101941645B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111154783A (en) * | 2020-01-16 | 2020-05-15 | 四川农业大学 | Application of maize ZmAKIN β gamma 1 gene in breeding lead stress resistant maize |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200132112A (en) | 2019-05-15 | 2020-11-25 | 한국원자력연구원 | Method for screening lactic acid bacteria for improving immunity using radioactive isotopes |
CN111172036A (en) * | 2019-12-24 | 2020-05-19 | 光明乳业股份有限公司 | Method for separating thallus from yoghourt and application of thallus in genome DNA extraction |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100725012B1 (en) * | 2005-08-09 | 2007-06-04 | 주식회사한국야쿠르트 | The new lactobacillus acidophilus HY 7036 isolated from korean adult, having high constipation improvement effect, high relieving intestinal disorders and high organic acid producibility, and products containing it |
KR101546224B1 (en) * | 2013-11-15 | 2015-08-21 | 재단법인 임실치즈과학연구소 | Preparation method for lactic acid bacteria isolated from kimchi yogurt using cinnamon extract |
KR101595014B1 (en) * | 2014-02-21 | 2016-02-18 | 재단법인 임실치즈과학연구소 | Method of fermented milk using lactobacillus |
-
2016
- 2016-08-29 KR KR1020160109879A patent/KR101941645B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111154783A (en) * | 2020-01-16 | 2020-05-15 | 四川农业大学 | Application of maize ZmAKIN β gamma 1 gene in breeding lead stress resistant maize |
Also Published As
Publication number | Publication date |
---|---|
KR20180000657A (en) | 2018-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Matsubara et al. | Treatment with probiotics in experimental oral colonization by Candida albicans in murine model (DBA/2) | |
KR101941645B1 (en) | Lactic acid bacteria strains derived from human body with excellent resistance to environmental stress and Method for producing yogurt using it | |
Zhang et al. | Screening and evaluation of lactic acid bacteria with probiotic potential from local Holstein raw milk | |
Mathipa et al. | Cocktails of probiotics pre-adapted to multiple stress factors are more robust under simulated gastrointestinal conditions than their parental counterparts and exhibit enhanced antagonistic capabilities against Escherichia coli and Staphylococcus aureus | |
Lohith et al. | In vitro probiotic characterization of yeasts of food and environmental origin | |
EP2124976B1 (en) | Growth inhibition and elimination of methicillin-resistant staphylococcus aureus by lactic acid bacteria | |
CN108018248B (en) | Lactobacillus casei capable of regulating flora structural disorder caused by antibiotics | |
KR101098946B1 (en) | A compound for feed additive comprising novel Lactobacillus salivarius G1-1 | |
CN106544287A (en) | One plant of moral formula lactobacillus with oxidation resistance and bacteriocinogeny | |
TWI404540B (en) | A novel strain of lactobacillus plantarum lp23 and its use in inhibition of helicobacter pylori | |
CN108935949B (en) | Feed antibiotic substitute composite preparation and preparation method thereof | |
CN110982731A (en) | Space-induced lactobacillus plantarum ST20-71 with probiotic characteristics and application thereof | |
KR20200107384A (en) | Novel Pediococcus pentosaceus FB145 with removing cadmium and use thereof | |
Mohammed et al. | Antimicrobial activity of probiotic lactobacilli against some pathogenic bacteria | |
KR101164512B1 (en) | Probiotic composition for animal comprising bifidobacterium pseudocatenulatum spm1204 or its culture | |
KR20160078688A (en) | Manufacturing method of probiotics powder containing goat milk | |
Sękowska et al. | New species of bacteria in human infections | |
Oh | Probiotics in dairy products | |
CN114921351B (en) | Pichia pastoris DPUY-F1 with probiotics function and application thereof in relieving colonitis symptoms | |
Asan-Ozusaglam et al. | Investigating the potential use of Pistacia terebinthus fruit extracts together with probiotic candidate lactic acid bacteria. | |
Muhammad et al. | Evaluation of probiotics potential of Lactobacilli isolated from Chinese traditional dairy products. | |
Fadaei et al. | Influence of Spirulina platensis powder on viability of Lactococcus strains in probiotic UF feta cheese containing Mentha longifolia L | |
Mazinani et al. | Viability of Lactobacillus acidophilus in sinbiotic ultrafiltration white cheese containing powdered Menthe longifolia L. and Spirulina platensis. | |
Al-Attwani | The effect of probiotics on bacterial human skin pathogens | |
Savitskaya et al. | Prospective Use of Probiotics Immobilized on Sorbents with Nanostructured Surfaces |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) |